Drug Trial Radar · NCT06847854
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
151
Actual
Start
Dec 8, 2022
Primary completion
Nov 16, 2026
Study completion Jan 18, 2027
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.
Conditions
- Diabetic Macular Edema
Interventions
RO7497372Drug
RO7497372 will be administered as IVT injection as per the schedule specified in the arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Adverse Events (AEs)Time frame: Up to 28 Weeks
- Part 2: Number of Participants With Intraocular Inflammation (IOI) AEs as Reported by the InvestigatorTime frame: Baseline to Week 48
- Part 2: Number of Participants With Severe or Serious Drug-Related IOI AEsTime frame: Baseline to Week 48
- Part 2: Number of Participants With Occlusive Retinal Vasculitis AEs as Reported by the InvestigatorTime frame: Baseline to Week 48
Locations
38 sites in 2 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Retinal Consultants of AZ, Ltd
Peoria, Arizona
Associated Retina Consultants
Phoenix, Arizona
Arkansas Retina Research
Little Rock, Arkansas
Global Research Management
Glendale, California
Retinal Consultants Medical Group
Modesto, California
Bay Area Retina Associates
Walnut Creek, California
Florida Eye Associates
Melbourne, Florida
Medeye Associates
South Miami, Florida
East Florida Eye Institute
Stuart, Florida
Retina Specialists of Tampa
Wesley Chapel, Florida
Center for Retina and Macula Disease
Winter Haven, Florida
Cumberland Valley Retina PC
Hagerstown, Maryland
Retina Associates of Michigan
Grand Blanc, Michigan
Foundation for Vision Research
Grand Rapids, Michigan
Retina Consultants Minnesota
Saint Louis Park, Minnesota
Mississippi Retina Associates
Madison, Mississippi
The Retina Institute
St Louis, Missouri
Sierra Eye Associates
Reno, Nevada
Ross Eye Institute
Buffalo, New York
Retina Associates of NY
New York, New York
Cleveland Clinic
Cleveland, Ohio
Verum Research LLC
Eugene, Oregon
EyeHealth Northwest
Portland, Oregon
Erie Retinal Surgery
Erie, Pennsylvania
Mid Atlantic Retina
Philadelphia, Pennsylvania
Carolina Eyecare Physicians
Mt. Pleasant, South Carolina
Charles Retina Institute
Germantown, Tennessee
Austin Clinical Research LLC
Austin, Texas
Brown Retina Institute
Schertz, Texas
Retina Consultants of Texas
The Woodlands, Texas
Salt Lake Retina
West Jordan, Utah
Retina Group of Washington
Fairfax, Virginia
Emerson Clinical Research Institute
Falls Church, Virginia
Piedmont Eye Center
Lynchburg, Virginia
Wagner Kapoor Institute
Norfolk, Virginia
Spokane Eye Clinic
Spokane, Washington
Emanuelli Research and Development Center LLC
Arecibo, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.